| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
|
|---|
| Outline of Final Research Achievements |
The aim of the present study was to assess the therapeutic and functional efficiency of targeting Janus kinase (JAK) and periodontal bacteria in patients with periodontitis and rheumatoid arthritis (RA). The results indicated that both the JAK- and the periodontal bacteria-targeting therapies exhibited an improvement of rheumatologic and periodontal inflammatory condition. The former therapies reduced serum levels of interleukin-6 and tumor necrosis factor, while the latter decreased serum protein spots in abundance which corresponds to blood and lipid metabolism-related components including apolipoprotein A1, angiotensinogen, and hemopexin. These results suggest the beneficial therapeutic effects of the JAK- and the periodontal bacteria-targeting therapies on rheumatologic and periodontal condition in patients with periodontitis and RA.
|
